Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well dasatinib works in treating patients with stage III
melanoma that cannot be removed by surgery or stage IV melanoma. Dasatinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.